Thymidine Kinase 1 Upregulation Is an Early Event in Breast Tumor Formation

被引:37
作者
Alegre, Melissa M. [1 ]
Robison, Richard A. [1 ]
O'Neill, Kim L. [1 ]
机构
[1] Brigham Young Univ, Dept Microbiol & Mol Biol, Provo, UT 84602 USA
关键词
D O I
10.1155/2012/575647
中图分类号
R73 [肿瘤学];
学科分类号
100214 [肿瘤学];
摘要
Prognostic markers play an important role in our understanding of tumors and how to treat them. Thymidine kinase 1 (TK1), a proliferation marker involved in DNA repair, has been shown to have independent prognostic potential. This prognostic potential includes the novel concept that upregulation of serum TK1 levels is an early event in cancer development. This same effect may also be seen in tumor tissue. In order to demonstrate that TK1 upregulation is an early event in tumor tissue formation, tissue arrays were obtained and stained for TK1 by immunohistochemistry. Using a progressive breast tissue array, precancerous tissue including breast adenosis, simple hyperplasia, and atypical hyperplasia stained positive for TK1 expression. Different stages of breast carcinoma tissue also stained positive for TK1 including nonspecific infiltrating duct, infiltrating lobular, and infiltrating duct with lymph node metastasis carcinomas. This indicates that TK1 upregulation is an early event in breast carcinoma development, and may be useful in identifying precancerous tissue. Further work is needed to better understand the differences seen between TK1 positive and negative tissues.
引用
收藏
页数:5
相关论文
共 20 条
[1]
Foekens JA, 2001, CANCER RES, V61, P1421
[2]
Thymidine kinase 1 expression defines an activated G1 state of the cell cycle as revealed with site-specific antibodies and ArrayScan™ assays [J].
Gasparri, Fabio ;
Wang, Naining ;
Skog, Sven ;
Galvani, Arturo ;
Eriksson, Staffan .
EUROPEAN JOURNAL OF CELL BIOLOGY, 2009, 88 (12) :779-785
[3]
Thymidine kinase 1 expression in atypical ductal hyperplasia significantly differs from usual ductal hyperplasia and ductal carcinoma in situ: A useful tool in tumor therapy management [J].
Guan, Hong ;
Sun, Yanhua ;
Zan, Qin ;
Xu, Meiquan ;
Li, Yuan ;
Zhou, Ji ;
He, Ellen ;
Eriksson, Staffan ;
Wen, Wen ;
Skog, Sven .
MOLECULAR MEDICINE REPORTS, 2009, 2 (06) :923-929
[4]
Thymidine Kinase 1 is a Potential Marker for Prognosis and Monitoring the Response to Treatment of Patients with Breast, Lung, and Esophageal Cancer and Non-Hodgkin's Lymphoma [J].
He, E. ;
Xu, X. H. ;
Guan, H. ;
Chen, Y. ;
Chen, Z. H. ;
Pan, Z. L. ;
Tang, L. L. ;
Hu, G. Z. ;
Li, Y. ;
Zhang, M. ;
Zhou, J. ;
Eriksson, S. ;
Fornander, T. ;
Skog, S. .
NUCLEOSIDES NUCLEOTIDES & NUCLEIC ACIDS, 2010, 29 (4-6) :352-358
[5]
He Q, 2006, ANTICANCER RES, V26, P4753
[6]
He QM, 2004, INT J ONCOL, V25, P945
[7]
Hengstschlager M, 1998, ADV EXP MED BIOL, V431, P455
[8]
Huang SQ, 2011, ASIAN PAC J CANCER P, V12, P497
[9]
Serological thymidine kinase 1 is a prognostic factor in oesophageal, cardial and lung carcinomas [J].
Li, Zhishan ;
Wang, Yinghong ;
He, Jie ;
Ma, Jie ;
Zhao, Liang ;
Chen, Hengqi ;
Li, Ning ;
Zhou, Ji ;
He, Ellen ;
Skog, Sven .
EUROPEAN JOURNAL OF CANCER PREVENTION, 2010, 19 (04) :313-318
[10]
A comparative study: Immunohistochemical detection of cytosolic thymidine kinase and proliferating cell nuclear antigen in breast cancer [J].
Mao, YR ;
Wu, JP ;
Wang, NN ;
He, LX ;
Wu, CJ ;
He, QM ;
Skog, S .
CANCER INVESTIGATION, 2002, 20 (7-8) :922-931